Abstract

Objective To investigate the effect of paclitaxel and gemcitabine on the expression of nucleosomal binding protein 1(NSBP1) in bladder cancer cell line T24 and its significance. Methods Reverse transcription PCR(RT-PCR) and western blotting were used to detect the expression of NSBP1 in bladder cancer cell T24 treated by different concentration(10% ,40% ,80% IC50) of paclitaxel and gemcitabine for 48 hours. Results RT-PCR showed that relative optical density (OD) of NSBP1 in bladder cancer cell T24 treated by 0%, 10%,40% and 80% IC50 paclitaxel were 0.392 ±0.024, 0.227±0.037, 0.135±0. 063 and 0.091 ±0.017, respectively (P<0.05). Relative OD of NSBP1 in bladder cancer cell T24 treated by 0%, 10%, 40% and 80% IC50 gemcitabine were 0.492±0.044, 0.262±0.031, 0.151±0.014 and 0.089±0.011, respectively. Western blotting showed that relative OD of NSBP1 in bladder cancer cell T24 treated by 0%, 10%,40% and 80% IC50 paclitaxel were 0.473±0.017, 0.252±0.041, 0.194±0.023 and 0.118±0.016, respectively. Relative OD of NSBP1 in bladder cancer cell T24 treated by 0, 10%, 40% and 80% IC50 gemcitabine were 0.581±0.014, 0.201±0.033, 0.135±0.021 and 0.114±0.011, respectively(P<0.05). Conclusion Paclitaxel and gemcitabine can decrease the expression level of NSBP1 in bladder cancer cell line T24 both in mRNA and protein levels, so NSBP1 may be one of the targets of chemotherapy. Key words: Urinary bladder neoplasms; HMGN1 protein; Chemotherapy

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.